Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Still Looking For A Cancer Vaccine Breakthrough, Roche Signs $200m Vaccibody Deal

Claims First Neoantigen Clinical Response In Advanced Cancer

Executive Summary

Despite a recent disappointment in a similar partnership with BioNTech, Genentech is pushing ahead with its neoantigen-targeting strategy.

You may also be interested in...



Denmark's IO Vaccine Biotech Attracts Investor Interest

Copenhagen-based start-up IO Biotech has raised a hefty €127m from a group of VC investors to accelerate its IDO- and PD-L1 targeted immuno-oncology approaches to the treatment of cancer.

R&D Trends Driving Broad Change In Surging Oncology Sector

Accounting for nearly a third of the global clinical pipeline, the oncology sector is set to grow to $250bn in sales by 2024 predicts a new report, identifying five research trends driving broad changes. COVID-19 has impacted trials, with 2% having been slowed down, suspended or discontinued.

Why Roche Oncology Bet Big On Neoantigen-Directed T-Cell Therapy

In an interview at J.P. Morgan, Roche's James Sabry explained why it wants to lead the pack in personalized, neoantigen-directed cellular therapy, after announcing tie-up with Adaptive Biotechnologies.

Topics

Related Companies

UsernamePublicRestriction

Register

OM011381

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel